Ensem Therapeutics Inc. has disclosed quinazoline derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Cellular senescence is a state of terminal cell cycle arrest that is being increasingly explored for its role in cancer therapeutics. Researchers from Ocean University of China reported on AS-1041, an anthraquinone compound derived from the marine compound Aspergiolide A, designed to be used against leukemia due to its pro-senescence effect.
The most comprehensive analysis of gene dependencies in cancer cells to date has identified 370 “highly enriched” drug targets in defined molecular backgrounds. This latest iteration of the Cancer Dependency Map, published in Cancer Cell, Jan. 11, 2024, builds on an earlier version published in 2019, which was based on 324 cell lines.
Insilico Medicine IP Ltd. has divulged cyclin-dependent kinase 8 (CDK8) and/or CDK19 dual inhibitors reported to be useful for the treatment of autoimmune diseases and cancer.
Medshine Discovery Inc. has identified EGFR (del19/Thr790Met/Cys797Ser triple mutant) inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Euregen Biopharma Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Biocytocgen Pharmaceuticals (Beijing) Co. Ltd. has entered into an exclusive option and license agreement with Radiance Biopharma Inc., granting Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC).
A landmark, real-world study in the U.K. has demonstrated that combining whole genome sequencing with clinical data enabled tailored cancer treatment and improved outcomes. At one health care center, having DNA sequence data led to changes from usual standard of care in 25% of cases. “Mostly, [patients] got into clinical trials; some got medicines they wouldn’t have got. Others avoided medicines because their genetic make-up suggested that if they were exposed to the medicines, they would be at risk of harm,” said Mark Caulfield, professor of clinical pharmacology at Queen Mary University of London, who is co-author of a paper outlining the findings in Nature Medicine, Jan 11, 2024.
RSS
